WHO ICTRP trial
A Phase II single centre, open-label study investigating the pharmacokinetics…
EUCTR2005-005742-39-LT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2005-005742-39-LT |
|---|---|
| Public title | A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formulation administered subcutaneously as two doses of 120 mg (given as 2 injections of 60 mg on Day 1 and repeated on Day 2) in patients with advanced prostate cancer |
| Scientific title | A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formulation administered subcutaneously as two doses of 120 mg (given as 2 injections of 60 mg on Day 1 and… |
| Primary sponsor | Ardana Bioscience Ltd |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Lithuania |
| Conditions | ADVANCED PROSTATE CANCER |
| Interventions | Product Name: TEVERELIX Product Code: ARD-03; ARD-06 Pharmaceutical Form: Suspension for injection Concentration unit: mg milligram(s) Concentration number: 120- |
| Registration date | Dec 20, 2005 |
| Target size | 8 |
| Secondary IDs | ARD-0301-008 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: